The British Journal of Clinical Pharmacology

Volume 31
1991

Published for
The British Pharmacological Society by
Blackwell Scientific Publications

© 1991 Blackwell Scientific Publications
Osney Mead, Oxford OX2 0EL
25 John Street, London WC1N 2BL
23 Ainslie Place, Edinburgh EH3 6AJ
3 Cambridge Center, Cambridge, Mass. 02142, USA
54 University Street, Carlton, Victoria 3053, Australia

Other Editorial Offices:
Arnette SA
2, rue Casimir-Delavigne
75006 Paris
France

Blackwell Wissenschaft
Meinekestrasse 4
D-1000 Berlin 15
Germany

Blackwell MZV
Feldgasse 13
A-1238 Wien
Austria

Published on behalf of
The British Pharmacological Society

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the copyright owner. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Blackwell Scientific Publications for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of $05.00 per copy is paid directly to CCC, 27 Congress Street, Salem, MA 01970, USA. 0306-5251/91 $05.00/0. (For copying beyond that permitted by Sections 107 or 108 of the US Copyright Law). This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Special requests should be addressed to the Editor.

Typeset by Oxprint Ltd, Oxford
Printed in Great Britain
at the University Press, Cambridge

Contents

Number 1, January 1991

Review

1 Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs: *R. J. MacFadyen, K. R. Lees & J. L. Reid*

Papers

15 A population study of the pharmacokinetics of felodipine: *E. Blychert, B. Edgar, D. Elmfeldt & T. Hedner*

25 Which vasodilator drug in patients with chronic heart failure? A randomised comparison of captopril and hydralazine: *P. M. Schofield, N. H. Brooks, G. P. Lawrence, H. J. Testa & C. Ward*

33 Arterial vasodilating profile and biological effects of pinacidil in healthy volunteers: *C. Thuillez, E. Pussard, E. Bellissant, C. Richer, R. Kechrid & J.-F. Giudicelli*

41 The effects of flosequinan on regional blood flow in normal man: *R. A. Scott, K. L. Woods & D. B. Barnett*

47 Differing calcium sensitivities of human cerebral and digital arteries, human metatarsal veins, and rat aorta: *V. Iwanov & R. F. W. Moulds*

55 Backtracking booze with Bayes—the retrospective interpretation of blood alcohol data: *P. R. Jackson, G. T. Tucker & H. F. Woods*

65 Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects: *J. G. Larkin, P. W. J. McKee, G. Forrest, G. H. Beastall, B. K. Park, J. I. Lowrie, P. Lloyd & M. J. Brodie*

73 Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine: *A. Herchuelz, D. Gangji, F. Derenne, J. Ph. Jeanniot & J. Douchamps*

77 The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients: *L. D. Lewis, D. L. Fitzgerald, P. Mohan, N. Thatcher, P. G. Harper & H. J. Rogers*

83 An evaluation of different ibuprofen preparations in the control of postoperative pain after third molar surgery: *R. A. Seymour, J. E. Hawkesford, M. Weldon & D. Brewster*

89 Inter- and intraindividual variability in the concentration-effect (sedation) relationships of flunitrazepam: *A. Grahnén, P. Wennerlund, B. Dahlström & S.-Å. Eckernäs*

93 Effects of granisetron and lorazepam, alone and in combination, on the EEG of human volunteers: *C. G. G. Link, T. J. Leigh & G. L. Fell*

Short reports

99 Effects of clonidine and yohimbine on the pupillary light reflex and carbachol-evoked sweating in healthy volunteers: *M. J. Morley, C. M. Bradshaw & E. Szabadi*

102 The pharmacokinetics of the enantiomers of flurbiprofen in patients with rheumatoid arthritis: *M. A. Young, L. Aarons & S. Toon*

105 A study of adjunctive copper sulphate treatment in patients with rheumatoid arthritis who have relapsed while taking D-penicillamine: *T. Pullar, H. Wrigley, K. Newton, C. Toothill & V. Wright*

108 Interaction between digoxin and indomethacin or ibuprofen: *H. S. Jørgensen, H. R. Christensen & J. P. Kampmann*

111 Prednisolone concentrations in cerebrospinal fluid after different prednisolone prodrugs: *M. Bührer, F. J. Frey & B. M. Frey*

114 The effects of enalapril and sulindac on the dermal response to substance P and neurokinin A: *R. E. Ferner, F. Kamali & M. D. Rawlins*

Letters to the Editors

117 Uses and misuses of definitions of genetic polymorphism. A perspective from population pharmacogenetics: *T. D. Arias, L. F. Jorge & R. Barrantes*

119 Phenotype or genotype?: *P. R. Jackson, A. R. Boobis & G. T. Tucker*

120 Enzyme-inducing properties of probenecid in man: *A. Bammel, H. Mönig, K. H. Zurborn, E. E. Ohnhaus & W. Kirch*

Book reviews

123 Methodological Errors in Research by B. Anderson: *R.E. Ferner*

124 European Pharmaceutical Policies—Comparative Study by P. Young: *M.D. Rawlins*

Number 2, February 1991

Papers

125 Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes: *C. J. Doecke, M. E. Veronese, S. M. Pond, J. O. Miners, D. J. Birkett, L. N. Sansom & M. E. McManus*

131 Effect of racemic ibuprofen dose on the magnitude and duration of platelet cyclo-oxygenase inhibition: relationship between inhibition of thromboxane production and the plasma unbound concentration of S(+)-ibuprofen: *A. M. Evans, R. L. Nation, L. N. Sansom, F. Bochner & A. A. Somogyi*

139 Inhibition of the metabolism of paracetamol by isoniazid: *M. M. Epstein, S. D. Nelson, J. T. Slattery, T. F. Kalhorn, R. A. Wall & J. M. Wright*

143 A comparison of the pharmacokinetic properties of streptokinase and anistreplase in acute myocardial infarction: *J. D. Gemmill, K. J. Hogg, J. M. A. Burns, A. P. Rae, F. G. Dunn, R. Fears, H. Ferres, R. Standring, H. Greenwood, D. Pierce & W. S. Hillis*

148 A study of the acute pharmacodynamic interaction of ramipril and felodipine in normotensive subjects: *A. D. Bainbridge, R. J. MacFadyen, K. R. Lees & J. L. Reid*

154 The effects of time and dose on the relative β_1- and β_2-adrenoceptor antagonism of betaxolol and atenolol: *B. J. Lipworth, N. A. Irvine & D. G. McDevitt*

160 Rapid reversal of α_2-adrenoceptor agonist effects by atipamezole in human volunteers: *S. Karhuvaara, A. Kallio, M. Salonen, J. Tuominen & M. Scheinin*

166 Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer: *M. S. Ching, G. W. Mihaly, P. W. Angus, D. J. Morgan, S. Devenish-Meares, N. D. Yeomans & R. A. Smallwood*

Short reports

171 Lack of a pharmacokinetic interaction between phenobarbitone and gabapentin: *W. D. Hooper, M. C. Kavanagh, G. K. Herkes & M. J. Eadie*

175 Lack of pharmacokinetic interaction between nifedipine, sparteine and phenytoin in man: *J. H. M. Schellens, P. A. Soons, J. H. F. van der Wart, J. W. Hoevers & D. D. Breimer*

179 Lack of effect of oral contraceptive use on the pharmacokinetics of quinine: *S. Wanwimolruk, S. Kaewvichit, O. Tanthayaphinant, C. Suwannarach & A. Oranratnachai*

182 The pharmacokinetics of postoperative intravenous ketorolac tromethamine in children: *K. T. Olkkola & E.-L. Maunuksela*

185 Pharmacokinetics of metoclopramide in patients with liver cirrhosis: *E. Magueur, H. Hagege, P. Attali, E. Singlas, J. P. Etienne & A. M. Taburet*

188 Geographical differences in adverse drug reaction reporting rates in the Northern Region: *D. N. Bateman, A. Lee, M. D. Rawlins & J. M. Smith*

190 Hospital prescribing and usage of hypnotics and anxiolytics: *C. Edwards, J. L. Bushnell, C. H. Ashton & M. D. Rawlins*

193 A dose-response study examining the effects of ritanserin on human slow wave sleep: *C. Idzikowski, F. J. Mills & R. J. James*

197 Influence of menstrual cycle phase on serum concentrations of α_1-acid glycoprotein: *R. C. Parish & C. Spivey*

200 Magnesium deficiency may be an important determinant of ventricular ectopy in digitalised patients with chronic atrial fibrillation: *R. Lewis, C. Durnin, J. McLay, J. McEwen & D. G. McDevitt*

204 A non-bronchoconstrictor, bacteriostatic preservative for nebuliser solutions: *Q. A. Summers, M. R. Nesbit, R. Levin & S. T. Holgate*

207 Effect of sulindac on the cough reflex of healthy subjects: *G. Foster, W. W. Yeo & L. E. Ramsay*

Letters to the Editors

209 Excretion of fluvoxamine in breast milk: *S. Wright, S. Dawling & J. J. Ashford*

210 The validity of the sigmoid E_{max} model and efficiency concept in diuretic studies: *G. Alván, M. Hammarlund-Udenaes & B. Odlind*

211 Pharmacological activity of the dinitrate metabolites of nitroglycerin following their oral administration to healthy volunteers: *M. Gumbleton & L. Z. Benet*

213 'First dose' hypotension and venodilatation: *S. Capewell & A. Capewell*

Proceedings

217 Proceedings of the British Pharmacological Society (University of Belfast, 12–14 September 1990)

Number 3, March 1991

Leading article

249 Clinical pharmacology in the United Kingdom—a view for the 1990s: *A. Breckenridge*

Review

251 Iron supplements: a common cause of drug interactions: *N. R. C. Campbell & B. B. Hasinoff*

Main papers

257 Clinical and chemical interactions between iron preparations and ciprofloxacin: *M. Kara, B. B. Hasinoff, D. W. McKay & N. R. C. Campbell*

263 The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac: *P. J. Neuvonen*

267 A comparison of the hypoalgesic effect of paracetamol in slow-release and plain tablets on laser-induced pain: *J. C. Nielsen, P. Bjerring & L. Arendt-Nielsen*

271 Measurement of glomerular function during cisplatin therapy: *D. G. Waller, L. Juer & J. S. Fleming*

275 Influence of acid secretory status on absorption of omeprazole from enteric coated granules: *T. Andersson, R. Bergstrand & C. Cederberg*

279 Population pharmacokinetics of quinidine: *K. Fattinger, S. Vozeh, H. R. Ha, M. Borner & F. Follath*

287 A competitive kinin receptor antagonist, [DArg^0, Hyp^3, DPhe^7]-bradykinin, does not affect the response to nasal provocation with bradykinin: *J. A. Pongracic, R. M. Naclerio, C. J. Reynolds & D. Proud*

295 Objective outcome criteria in trials of anti-Parkinsonian therapy in the elderly: sensitivity, specificity and reliability of measures of brady- and hypo-kinesia: *S. G. Bowes, P. K. Clark, A. Charlett, C. J. A. O'Neill, A. L. Leeman, C. Weller, P. W. Nicholson, A. A. Deshmukh, S. M. Dobbs & R. J. Dobbs*

305 A comparison of the chronic effects of oral xamoterol and enalapril on blood pressure and renal function in mild to moderate heart failure: *M. J. Jamieson, J. Webster, G. Fowler, J. Rawles, F. W. Smith & J. C. Petrie*

313 Pharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension: *G. Mikus, V. Mast, C. Fischer, C. Machleidt, U. Kuhlmann & M. Eichelbaum*

323 Evaluation of potential pharmacodynamics and pharmacokinetic interactions between verapamil and propranolol in normal subjects: *D. L. Murdoch, G. D. Thomson, G. G. Thompson, G. D. Murray, M. J. Brodie & G. T. McInnes*

Short reports

333 Effects of granisetron and lorazepam, alone and in combination, on psychometric performance: *T. J. Leigh, C. G. G. Link & G. L. Fell*

337 Human responses to inhaled capsaicin are not inhibited by granisetron: *N. B. Choudry, J. R. McEwan, E. A. Lavender, A. J. Williams & R. W. Fuller*

340 Simvastatin in severe hypercholesterolaemia: a placebo controlled trial: *J. F. W. McDowell, M. Smye, T. Trinick, J. A. Shortt, M. P. Archibald, E. R. Trimble & D. P. Nicholls*

344 Cyclosporin metabolism by the gastrointestinal mucosa: *J. F. Tija, I. R. Webber & D. J. Back*

347 Effects of an EDTA infusion on the urinary elimination of several elements in healthy subjects:

P. Allain, Y. Mauras, A. Premel-Cabic, S. Islam, J. P. Herve & J. Cledes

350 Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies: *Y. Zhang, R. A. Blouin, P. J. McNamara, J. Steinmetz & P. J. Wedlund*

353 The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates: *H. Sakai, S. Kobayashi, K. Hamada, S. Iida, H. Akita, E. Tanaka, E. Uchida & H. Yasuhara*

356 Cough and enalapril: assessment by spontaneous reporting and visual analogue scale under double-blind conditions: *W. W. Yeo, D. Maclean, P. J. Richardson & L. E. Ramsay*

360 Cardiovascular effects of a chlorpheniramine/paracetamol combination in hypertensive patients who were sensitive to the pressor effect of pseudoephedrine: *S. S. Chua, S. I. Benrimoj, R. D. Gordon & G. Williams*

363 Interaction of indomethacin and sulindac with labetalol: *M. A. Abate, J. L. Neely, R. D. Layne & R. D'Alessandri*

367 A comparison of the pharmacokinetics of nisoldipine in elderly and young subjects: *A. K. Baksi, J. S. Edwards & G. Ahr*

Letter to the Editors

371 The effects of plasmapheresis on thyroid hormone and plasma drug concentrations in amiodarone-induced thyrotoxicosis: *B. Uzzan, E. Pussard, A. Leon, D. Bekhechi, A. Krivitzky, E. Modigliani, G. Perret, R. Vassy, A. Berdeaux & J. F. Giudicelli*

Number 4, April 1991

Review

373 Influence of ACE inhibitors on free radicals and reperfusion injury: pharmacological curiosity or therapeutic hope?: *J. McMurray & M. Chopra*

Papers

381 Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers: *Z. R. Chen, A. A. Somogyi, G. Reynolds & F. Bochner*

391 Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects: *R. V. Lewis, L. E. Ramsay, P. R. Jackson, W. W. Yeo, M. S. Lennard & G. T. Tucker*

399 Ethnic differences in the pharmacokinetics of oral nifedipine: *C. H. Ahsan, A. G. Renwick, B. Macklin, V. F. Challenor, D. G. Waller & C. F. George*

405 Caffeine renal clearance and urine caffeine concentrations during steady state dosing. Implications for monitoring caffeine intake during sports events: *D. J. Birkett & J. O. Miners*

409 Hearing impairment related to plasma quinine concentration in healthy volunteers: *G. Alván, K. K. Karlsson, U. Hellgren & T. Villén*

413 The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers: *D. R. C. Robertson, I. Higginson, B. S. Macklin, A. G. Renwick, D. G. Waller & C. F. George*

419 Disposition of γ-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers: *Y. A. Boateng, H. E. Barber, T. M. MacDonald, J. C. Petrie & M. R. Lee*

423 Intravenous strontium gluconate as a kinetic marker for calcium in healthy volunteers: *M. E. A. Moraes, J. K. Aronson & D. G. Grahame-Smith*

429 Cerebral blood flow and indomethacin drug levels in subjects with and without central nervous side effects: *P. Seideman & M. Von Arbin*

433 Human jejunal secretion induced by prostaglandin E_1: a dose-response study: *I. Sobhani, N. Vidon, B. Huchet & J. C. Rambaud*

439 Acute reduction of TxA_2 platelet binding sites after *in vivo* administration of a TxA_2 receptor inhibitor: *P. A. Modesti, A. Colella, I. Cecioni, G. F. Gensini, R. Abbate & G. G. Neri Serneri*

445 A method for bioassay of potency and effectiveness of inhaled bronchodilators in normal subjects: *R. W. Foster, G. K. Atanga, J. R. Carpenter, D. E. Evans, K. Rakshi & R. C. Small*

457 Adequacy of twice daily dosing with potassium chloride and spironolactone in thiazide treated hypertensive patients: *J. M. Toner, L. A. Brawn, W. W. Yeo & L. E. Ramsay*

463 Analysis of the natriuretic action of a loop diuretic, piretanide, in man: *F. H. Noormohamed & A. F. Lant*

471 Skin irritation induced by topically applied timolol: *K. Kubota, E. Koyama & K. Yasuda*

477 Subjective and objective assessment of enalapril in primary Raynaud's phenomenon: *V. F. Challenor, D. G. Waller, R. A. Hayward, M. J. Griffin & O. S. Roath*

Short reports

481 The effects of cimetidine and ranitidine on the pharmacokinetics of cifenline: *J. W. Massarella, T. M. Defeo, J. Liguori, S. Passe & K. Aogaichi*

484 Pharmacokinetics of halofantrine in Thai patients with acute uncomplicated falciparum malaria: *J. Karbwang, K. A. Milton, K. Na Bangchang, S. A. Ward, G. Edwards & D. Bunnag*

488 Effect of zinc supplementation on oxidative drug metabolism in patients with hepatic cirrhosis: *M. G. Barry, P. Macmathuna, K. Younger, P. W. N. Keeling & J. Feely*

Book reviews

493 Early Phase Drug Evaluation in Man edited by J. O'Grady and O. I. Linet: *G. R. Venning*

494 Animal Toxicity Studies: Their Relevance for Man edited by C. E. Lumley and S. R. Walker: *M. L'E. Orme*

Number 5, May 1991

Leading article

495 The scope of clinical pharmacology in the pharmaceutical industry: *N. S. Baber*

Meeting report

497 The roles and responsibilities of clinical pharmacology: *J. Collier & A. Herxheimer*

Lilly Prize Lecture

501 A way of looking at agonism and antagonism: lessons from salbutamol, salmeterol and other β-adrenoceptor agonists: *D. Jack*

Main papers

515 Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug: *M. Sedgwick, H. S. Rasmussen, D. Walker & S. M. Cobbe*

521 The effect of intra-arterial endothelin on resting blood flow and sympathetically mediated vasoconstriction in the forearm of man: *J. R. Cockcroft, J. G. Clarke & D. J. Webb*

525 Evaluation of drug information for cardiology patients: *D. Baker, D. E. Roberts, R. G. Newcombe & K. A. A. Fox*

533 Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer: *J.-C. Duche, C. Joanne, J. Barre, H. de Cremoux, J. C. Dalphin, A. Depierre, P. Brochard, J. P. Tillement & P. Bechtel*

537 Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease: *J. Radermacher, D. Jentsch, M. A. Scholl, T. Lustinetz & J. C. Frölich*

Short reports

543 The comparative pharmacokinetics of acemetacin in young subjects and elderly patients: *R. W. Jones, A. J. Collins, L. J. Notarianni & E. Sedman*

546 Diflunisal and its conjugates in patients with renal failure: *R. G. Dickinson, R. K. Verbeeck, A. R. King, A. C. Restifo & S. M. Pond*

551 A comparison of drug protein binding and α_1-acid glycoprotein concentration in Chinese and Caucasians: *J. Feely & T. Grimm*

553 A comparison of serum and saliva paracetamol concentrations: *M. Smith, E. Whitehead, G. O'Sullivan & F. Reynolds*

556 Mefloquine pharmacokinetics and resistance in children with acute falciparum malaria: *F. Nosten, F. ter Kuile, T. Chongsuphajaisiddhi, K. Na Bangchang, J. Karbwang & N. J. White*

560 Transdermal nitrate therapy: bioavailability during exercise increases transiently after the daily change of patch: *K. Gjesdal, T. O. Klemsdal, E. O. Rykke & J. E. Bredesen*

Proceedings

563 Proceedings of the British Pharmacological Society (St George's Hospital Medical School, 17–19 December 1990)

Number 6, June 1991

Editorial

619 The Journal in the 1990s: *L. E. Ramsay & G. T. Tucker*

List of Referees 1990

Leading article

623 Clinical pharmacology through the looking glass: reflections on the racemate *vs* enantiomer debate: *M. S. Lennard*

Review

627 The description and prediction of antihypertensive drug response: an individualised approach: *R. Donnelly, P. A. Meredith & H. L. Elliott*

Papers

635 Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine: *Q. Y. Yue, J. Hasselström, J. O. Svensson & J. Säwe*

643 A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine: *Q. Y. Yue, J. O. Svensson, F. Sjöqvist & J. Säwe*

649 A screening test for slow metabolisers of tolbutamide: *M. A. Page, J. S. Boutagy & G. M. Shenfield*

655 Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase): *R. F. Tyndale, W. Kalow & T. Inaba*

661 Interindividual variability in the glucuronidation and sulphation of ethinyloestradiol in human liver: *A. Temellini, L. Giuliani & G. M. Pacifici*

665 Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin: *H. Y. Pan, J. Triscari, A. R. DeVault, S. A. Smith, D. Wang-Iverson, B. N. Swanson & D. A. Willard*

671 Pharmacokinetics and pharmacodynamics of a new transdermal delivery system for bopindolol: *J. Drewe, R. Meier, U. Timonen, M. Thumshirn, J. Munzer, T. Kissel & K. Gyr*

677 Faster and more reliable absorption of adrenaline by aerosol inhalation than by subcutaneous injection: *H. Mellem, K. Lande, S. E. Kjeldsen, A. Westheim, I. Eide, P. F. Ekholt & N. P. Boye*

683 The effect of cisapride on gastro-oesophageal dysfunction in systemic sclerosis: a controlled manometric study: *A. Kahan, S. Chaussade, M. Gaudric, B. Freitag, B. Amor, C. J. Menkes, G. Strauch, J. Guerre & D. Couturier*

Short reports

689 The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism – a panel study: *S. A. Ward, N. A. Helsby, E. Skjelbo, K. Brøsen, L. F. Gram & A. M. Breckenridge*

693 Metabolism of verapamil in a family pedigree with deficient *N*-oxidation of trimethylamine: *R. Ayesh, H. Kroemer, M. Eichelbaum & R. L. Smith*

697 The effect of renal impairment on the

pharmacokinetics and metabolism of bopindolol: *N. J. Macdonald, A. C. Grant, R. S. C. Rodger, P. A. Meredith & H. L. Elliott*

701 Renal and neurohumoral effects of ibopamine and metoclopramide in normal man: *A. R. J. Girbes, D. J. Van Veldhuisen, A. J. Smit, A. Drent-Bremer, S. Meijer & W. D. Reitsma*

705 Lithium does not alter the renal response to a pressor dose of tyramine in man: *C. C. Lang, A. R. Rahman & A. D. Struthers*

708 Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine: *J. Bonde, L. E. Pedersen, E. Nygaard, T. Ramsing, H. R. Angelo & J. P. Kampmann*

711 Pentoxifylline stimulates human sperm motility both *in vitro* and after oral therapy: *M-R. Shen, P-H. Chiang, R-C. Yang, C-Y. Hong & S-S. Chen*

715 Ponalrestat does not cause a protein binding interaction with warfarin in diabetic patients: *R. F. W. Moulds, R. O. Fullinfaw, R. W. Bury, W. E. Plehwe, N. Jacka, K. M. McGrath & F. I. R. Martin*

719 Single dose pharmacokinetics and pharmacodynamics of oral oxazepam in very elderly institutionalised subjects: *J. Sonne, S. Loft, M. Døssing, S. Boesgaard & F. Andreasen*

Letter to the Editors

723 The effect of pindolol on creatine kinase is not due to β_2-adrenoceptor partial agonist activity: *N. M. Wheeldon, D. M. Newnham, G. C. Fraser, D. G. McDevitt & B. J. Lipworth*

725 Author and Subject Indexes to Volume 31